+44 20 8123 2220
info@marketpublishers.com

RCC [2017]: Bulletin #1

https://marketpublishers.com/r/RCB785D7473EN.html
Date: August 2017
Pages: 0
Price: US$ 1,045.00 (Single User License)
ID: RCB785D7473EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; data released from Bristol-Myers Squibb's Phase III CheckMate-214 study, comparing Opdivo (nivolumab) in combination with ipilimumab (Yervoy) versus Sutent (sunitinib; Pfizer) in intermediate and poor-risk patients with previously untreated advanced or metastatic RCC;Exelixis and Bristol-Myers Squibb's initiation of the Phase III CheckMate 9ER trial to evaluate Opdivo in combination with Cabometyx (cabozantinib), or Opdivo and ipilimumab in combination with Cabometyx, versus Sutent in patients with previously untreated, advanced or metastatic RCC; Exelixis' filing for US FDA approval of Cabometyx for the treatment of patients with previously untreated advanced RCC, based on data from the Phase II CABOSUN trial.

Business Questions:

How do KOLs interpret the findings from the CheckMate-214 trial of Bristol-Myers Squibb's Opdivo/ipilimumab combination?

What is the likelihood of favourable OS data coming out of the CheckMate-214 trial?

Does the Opdivo/ipilimumab combination have potential in the treatment of intermediate and poor-risk patients with previously untreated advanced or metastatic RCC, and what are the expectations for use?

To what extent will tolerability issues affect the likely potential of Opdivo/ipilimumab/Cabometyx and Opdivo/ipilimumab combination regimens in patients with previously untreated advanced or metastatic RCC?

+44 20 8123 2220
info@marketpublishers.com

What other barriers to standard practice will Opdivo/ipilimumab/Cabometyx and Opdivo/ipilimumab combination regimens face?

How likely is it that the US FDA will approve Exelixis' Cabometyx for the treatment of patients with previously untreated advanced RCC, based on data from the Phase II CABOSUN trial?

What competition will Cabometyx face, if approved for the treatment of previously untreated advanced RCC?

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: RCC [2017]: Bulletin #1
Product link: https://marketpublishers.com/r/RCB785D7473EN.html
Price: US$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/RCB785D7473EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970